9,652 Shares in C4 Therapeutics, Inc. (NASDAQ:CCCC) Acquired by Headlands Technologies LLC

Headlands Technologies LLC bought a new position in C4 Therapeutics, Inc. (NASDAQ:CCCC) in the 2nd quarter, Holdings Channel.com reports. The fund bought 9,652 shares of the company’s stock, valued at approximately $45,000.

A number of other hedge funds and other institutional investors have also modified their holdings of CCCC. Vanguard Group Inc. increased its position in C4 Therapeutics by 46.0% during the first quarter. Vanguard Group Inc. now owns 2,920,028 shares of the company’s stock worth $23,857,000 after buying an additional 920,627 shares during the last quarter. Commodore Capital LP acquired a new position in shares of C4 Therapeutics during the 4th quarter valued at about $21,470,000. Wasatch Advisors LP raised its stake in shares of C4 Therapeutics by 14.3% in the 4th quarter. Wasatch Advisors LP now owns 7,138,949 shares of the company’s stock valued at $40,335,000 after acquiring an additional 891,808 shares in the last quarter. Hennion & Walsh Asset Management Inc. bought a new stake in C4 Therapeutics during the second quarter worth approximately $660,000. Finally, Entropy Technologies LP acquired a new position in C4 Therapeutics during the first quarter valued at approximately $126,000. Institutional investors own 78.81% of the company’s stock.

C4 Therapeutics Trading Up 1.6 %

CCCC opened at $6.46 on Wednesday. C4 Therapeutics, Inc. has a 1-year low of $1.06 and a 1-year high of $11.88. The business has a 50 day moving average of $6.16 and a 200-day moving average of $6.43. The stock has a market capitalization of $444.49 million, a price-to-earnings ratio of -2.73 and a beta of 3.05.

C4 Therapeutics (NASDAQ:CCCC) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.11. The company had revenue of $12.01 million for the quarter, compared to analyst estimates of $6.88 million. C4 Therapeutics had a negative net margin of 367.17% and a negative return on equity of 44.60%. Equities analysts predict that C4 Therapeutics, Inc. will post -1.57 EPS for the current year.

Analysts Set New Price Targets

Separately, BMO Capital Markets restated an “outperform” rating and issued a $20.00 price objective on shares of C4 Therapeutics in a research note on Tuesday, August 6th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $9.29.

C4 Therapeutics Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.